Aflibercept: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted aflibercept, while AWMSG (Wales) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “In combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is res…”, while AWMSG (Wales) recorded not recommended for “In combination with irinotecan/5 fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic…”.
HAS (France) has been harder on aflibercept than on its own caseload: it refused 4 of 11 decisive submissions here (36%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 13.7 years separate the first record, 29 Nov 2012 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
NYE METODER (Norway) changed its position: not recommended on 14 Dec 2014, recommended by 15 Mar 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for aflibercept, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 23 of 67 records date from 2023 or later.
The programme is broad: 24 distinct indication wordings are recorded for aflibercept by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
14 of these 67 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess aflibercept, on 29 Nov 2012; DMC (Denmark) did not open a file until 25 Apr 2024 — an unusually long tail of 11.4 years between the earliest and latest system to look at it.
The record arrives in waves: 12 separate years each carry two or more decisions, spread across 14 years in total.
11 of the 11 agencies here assessed aflibercept more than once, PBAC (Australia) most often at 14 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for aflibercept.
The full ledger for aflibercept reads 36 recommended, 11 not recommended, 5 no benefit and 4 deferred to NICE, with 11 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 17 Jun 2026 | Indicaciones terapéuticas autorizadas: Eylea está indicado en adultos para el tratamiento de: • la degeneración macular … | not financed by the SNS · art. 92 d | source |
| DMC (Denmark) | 27 May 2026 | Aflibercept 8 mg er indiceret til behandling af makulaødem sekundært til retinal veneokklusion (RVO) (grenveneokklusion … | Direkte indplacering | source |
| NYE METODER (Norway) | 15 Mar 2026 | Til behandling av nedsatt syn som følge av makulaødem sekundært til retinal veneokklusjon. | introduced | source |
| AWMSG (Wales) | 14 Feb 2025 | For the treatment in adults of neovascular (wet) age-related macular degeneration (nAMD) visual impairment due to diabet… | excluded, NICE appraised | source |
| PBAC (Australia) | 2024 | Diabetic macular oedema (DMO) | Not Applicable | source |
62 further decisions for aflibercept, across 11 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 41 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
- everolimus — same ATC class L01X — Antineoplastics
Coverage: 67 decisions for aflibercept from 11 agencies, 2012 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.